Provided by Tiger Trade Technology Pte. Ltd.

ProKidney Corp.

1.55
-0.0600-3.73%
Post-market: 1.610.0600+3.87%19:59 EDT
Volume:891.26K
Turnover:1.41M
Market Cap:468.19M
PE:-2.95
High:1.64
Open:1.58
Low:1.53
Close:1.61
52wk High:7.13
52wk Low:0.5400
Shares:302.06M
Float Shares:191.79M
Volume Ratio:0.97
T/O Rate:0.46%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.5255
EPS(LYR):-0.5150
ROE:-49.37%
ROA:-30.15%
PB:-0.46
PE(LYR):-3.01

Loading ...

Company Profile

Company Name:
ProKidney Corp.
Exchange:
NASDAQ
Establishment Date:
2015
Employees:
231
Office Location:
2000 Frontis Plaza Boulevard,Suite 250,Winston-Salem,North Carolina,United States
Zip Code:
27103
Fax:
- -
Introduction:
ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

Directors

Name
Position
Bruce Culleton
Chief Executive Officer and Director
Pablo Legorreta
Chairman of the Board and Director
William F. Doyle
Lead Independent Director
Alan M. Lotvin
Director
Brian J. G. Pereira
Director
Jennifer Fox
Director
Jose Ignacio Jimenez Santos
Director
Uma Sinha
Director

Shareholders

Name
Position
Bruce Culleton
Chief Executive Officer and Director
James Coulston
Chief Financial Officer
Darin J. Weber
Chief Regulatory Officer
Todd C. Girolamo
Chief Legal Officer